Literature DB >> 12578151

Invasive pulmonary aspergillosis: identification of risk factors.

Mohamed Farouk Allam1, Amparo Serrano Del Castillo, Carmen Díaz-Molina, Rafael Fernández-Crehuet Navajas.   

Abstract

Aspergillosis is the second most frequent fungal infection after candidiasis in teaching hospitals. Clinical manifestations of pulmonary aspergillosis range from asymptomatic colonization to disseminated disease. The aim of this study was to identify the risk factors associated with invasive pulmonary aspergillosis, in patients with positive pulmonary isolation of Aspergillus species. A review was undertaken of all clinical records with pulmonary isolation of Aspergillus species at Reina Sofia University Hospital from January 1995 to December 1998. Data collected were: age, gender, history of smoking, past medical history, such as chronic pulmonary disease, immunosuppression, granulocytopenia in the past 6 months and during the last admission, history of surgery including within the last year of the study period, number of hospital admissions and clinical evidence of invasive pulmonary aspergillosis. To investigate all the possible risk factors for invasive pulmonary aspergillosis, a multivariable logistic regression model was used. 132 patients with positive pulmonary isolation were identified, of which 42.4% had clinical evidence of invasive pulmonary aspergillosis. The independent factors significantly associated with invasive pulmonary aspergillosis were: granulocytopenia in the past 6 months, immunosuppression in the last admission and the number of hospital admissions within the past year. Patients with a history of granulocytopenia in the past 6 months and immunosuppression in the last admission are the high-risk group for invasive pulmonary aspergillosis. However, invasive pulmonary aspergillosis can also occur in mild granulocytopenic or even immunocompetent patients.

Entities:  

Mesh:

Year:  2002        PMID: 12578151     DOI: 10.1080/0036554021000026954

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  8 in total

Review 1.  Infection prevention in the cancer center.

Authors:  Kerri A Thom; Michael Kleinberg; Mary-Claire Roghmann
Journal:  Clin Infect Dis       Date:  2013-05-07       Impact factor: 9.079

2.  Acute Kidney Injury in a Patient on High-dose Glucocorticoid Therapy.

Authors:  Lanny T DiFranza; Dominick Santoriello
Journal:  Kidney360       Date:  2021-10-28

Review 3.  Tracheobronchial manifestations of Aspergillus infections.

Authors:  Rafal Krenke; Elzbieta M Grabczak
Journal:  ScientificWorldJournal       Date:  2011-11-20

Review 4.  Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species.

Authors:  L Drgona; A Khachatryan; J Stephens; C Charbonneau; M Kantecki; S Haider; R Barnes
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-09-12       Impact factor: 3.267

5.  A case of invasive pulmonary aspergillosis with direct invasion of the mediastinum and the left atrium in an immunocompetent patient.

Authors:  Kyu-Hyun Han; Jung-Hyun Kim; Sun Young Shin; Hye Yun Jeong; Ji Min Chu; Hak Su Kim; Daejin Kim; Minjung Shim; Sang-Ho Cho; Eun Kyung Kim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2014-07-31

6.  A risk prediction score for invasive mold disease in patients with hematological malignancies.

Authors:  Marta Stanzani; Russell E Lewis; Mauro Fiacchini; Paolo Ricci; Fabio Tumietto; Pierluigi Viale; Simone Ambretti; Michele Baccarani; Michele Cavo; Nicola Vianelli
Journal:  PLoS One       Date:  2013-09-26       Impact factor: 3.240

7.  Invasive Aspergillosis Involving the Mediastinum in an Immunocompetent Patient: A Case Report.

Authors:  Manesh Kumar Gangwani; Muhammad Aziz; Siraj Munir; Syed Ahsan Ali
Journal:  Cureus       Date:  2017-08-24

8.  Invasive mediastinal aspergillosis presenting as superior vena cava syndrome in an immunocompetent patient.

Authors:  Yasmin Rahim; Aisha Memon; Javaid Ahmed Khan
Journal:  BMJ Case Rep       Date:  2018-09-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.